---
run_id: halo-evidence-vs-diagnosis-validation-v12-vanilla-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: vanilla
run_number: 8
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 801
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
condition_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
output_file: model-outputs/vanilla-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `vanilla`, run 8 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 801, on the frozen condition packet.

## Output

I recommend the **Case Evidence Review**.

### The Recommendation
You should advise the CEO to commit to the Case Evidence Review. While the financial metrics look strong, they are currently "noisy"—inflated by temporary pricing bundles and skewed by sales narratives. The core risk is that you have built a tool that managers *like* (for oversight) but analysts *distrust or cannot use* (for execution).

The Case Evidence Review is the only option that penetrates the "black box" of the actual workflow. By analyzing whether suggestions are accepted, overridden, or unexplainable, you move from measuring **activity** (which is currently vanity-driven by managers rerunning samples) to measuring **efficacy**. This provides the only reliable foundation for next year's budget: knowing if PlanPilot is a scalable value-driver or a polished demo that fails under operational scrutiny.

### The Strongest Reason Against It
The Case Evidence Review is a "slow" qualitative audit in a high-pressure quantitative environment. It does not provide the immediate, boardroom-ready "green light" that a Demand Cleanroom (sales validation) or an Adoption Quality Sprint (usage data) offers. By choosing this, you are sacrificing the ability to prove immediate commercial demand or rapid usage growth to the board in twelve days; you are choosing operational truth over perceived momentum.

### The Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the two regional administrators planning to remove PlanPilot did so because of **pricing/budgetary constraints** rather than **product utility**.

If the "churn" is purely financial, your problem is a pricing strategy issue (solved by the Cleanroom). However, if the churn—and the public-sector abandonment—is because the tool is a "black box" that analysts cannot defend to their reviewers, you have a fundamental product-market fit failure. Given the current evidence of analysts falling back to manual notes and public-sector abandonment, the risk is likely utility, not price.
